Asset Details
Do you wish to reserve the book?
SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodeling
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodeling
Do you wish to request the book?
SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodeling
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodeling
2024
Overview
Serum response factor (SRF) controls gene transcription in vascular smooth muscle cells (VSMCs) and regulates VSMC phenotypic switch from a contractile to a synthetic state, which plays a key role in the pathogenesis of cardiovascular diseases (CVD). It is not known how post-translational SUMOylation regulates the SRF activity in CVD. Here we show that
Senp1
deficiency in VSMCs increased SUMOylated SRF and the SRF-ELK complex, leading to augmented vascular remodeling and neointimal formation in mice. Mechanistically, SENP1 deficiency in VSMCs increases SRF SUMOylation at lysine 143, reducing SRF lysosomal localization concomitant with increased nuclear accumulation and switching a contractile phenotype-responsive SRF-myocardin complex to a synthetic phenotype-responsive SRF-ELK1 complex. SUMOylated SRF and phospho-ELK1 are increased in VSMCs from coronary arteries of CVD patients. Importantly, ELK inhibitor AZD6244 prevents the shift from SRF-myocardin to SRF-ELK complex, attenuating VSMC synthetic phenotypes and neointimal formation in
Senp
1-deficient mice. Therefore, targeting the SRF complex may have a therapeutic potential for the treatment of CVD.
How post-translational SUMOylation regulates the SRF activity in cardiovascular disease is unclear. Here, the authors report that SRF SUMOylation increased by SENP1 deficiency switches vascular smooth muscle cells from a healthy contractile phenotype to a disease-associated synthetic phenotype.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 13/109
/ 13/51
/ 13/95
/ 14/1
/ 14/19
/ 14/63
/ 38/22
/ 38/23
/ 64/110
/ 96
/ Animals
/ Cardiovascular Diseases - genetics
/ Cardiovascular Diseases - metabolism
/ Cardiovascular Diseases - pathology
/ Cysteine Endopeptidases - genetics
/ Cysteine Endopeptidases - metabolism
/ ets-Domain Protein Elk-1 - genetics
/ ets-Domain Protein Elk-1 - metabolism
/ Humanities and Social Sciences
/ Humans
/ Lysine
/ Male
/ Mice
/ Muscle, Smooth, Vascular - metabolism
/ Muscles
/ Myocytes, Smooth Muscle - metabolism
/ Nuclear Proteins - metabolism
/ Science
/ Serum Response Factor - genetics
/ Serum Response Factor - metabolism
